sarpogrelate has been researched along with Myocardial Infarction in 9 studies
sarpogrelate: structure given in first source
Myocardial Infarction: NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose of this study was to assess the potential benefit of a 5-hydroxytryptamine receptor antagonist, sarpogrelate-based triple antiplatelet therapy (TAPT) in comparison with dual antiplatelet therapy (DAPT) in patients undergoing primary percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI)." | 7.85 | Sarpogrelate Based Triple Antiplatelet Therapy Improved Left Ventricular Systolic Function in Acute Myocardial Infarction: Retrospective Study. ( Cho, JR; Choi, JH; Choi, S; Chun, KJ; Kang, MK; Lee, N; Park, SM; Pierres, F; Shaha, KB; Sumiya, T, 2017) |
| " This study examined the effect of sarpogrelate, a 5-HT(2A) receptor blocker, in preventing cardiac dysfunction due to myocardial infarction (MI)." | 7.71 | Blockade of 5-HT(2A) receptors by sarpogrelate protects the heart against myocardial infarction in rats. ( Brasil, D; Dhalla, NS; Kumamoto, H; Kumar, K; Takeda, N; Temsah, RM, 2002) |
| "The purpose of this study was to assess the potential benefit of a 5-hydroxytryptamine receptor antagonist, sarpogrelate-based triple antiplatelet therapy (TAPT) in comparison with dual antiplatelet therapy (DAPT) in patients undergoing primary percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI)." | 3.85 | Sarpogrelate Based Triple Antiplatelet Therapy Improved Left Ventricular Systolic Function in Acute Myocardial Infarction: Retrospective Study. ( Cho, JR; Choi, JH; Choi, S; Chun, KJ; Kang, MK; Lee, N; Park, SM; Pierres, F; Shaha, KB; Sumiya, T, 2017) |
| "Sarpogrelate-containing triple antiplatelet therapy demonstrated comparable rates of MACCE prevention to the conventional dual antiplatelet therapy after PCI without significantly increasing bleeding risk during the two-year follow-up period." | 3.83 | Antiplatelet Therapy of Cilostazol or Sarpogrelate with Aspirin and Clopidogrel after Percutaneous Coronary Intervention: A Retrospective Cohort Study Using the Korean National Health Insurance Claim Database. ( Bae, SK; Kim, GJ; Kim, JH; Lee, J; Lee, S; Lim, HS; Noh, Y; Oh, E; Shin, S, 2016) |
| " This study examined the effect of sarpogrelate, a 5-HT(2A) receptor blocker, in preventing cardiac dysfunction due to myocardial infarction (MI)." | 3.71 | Blockade of 5-HT(2A) receptors by sarpogrelate protects the heart against myocardial infarction in rats. ( Brasil, D; Dhalla, NS; Kumamoto, H; Kumar, K; Takeda, N; Temsah, RM, 2002) |
| "Sarpogrelate (4 mg/kg) was infused intravenously for 30 min either before LCA occlusion or at reperfusion." | 1.33 | 5-HT2 receptor blocker sarpogrelate prevents downregulation of antiapoptotic protein Bcl-2 and protects the heart against ischemia-reperfusion injury. ( Maeda, H; Murio, Y; Rajesh, KG; Sasaguri, S; Suzuki, R, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 4 (44.44) | 29.6817 |
| 2010's | 3 (33.33) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Fouad Shalaby, MA | 1 |
| Abd El Latif, HA | 1 |
| El Yamani, M | 1 |
| Galal, MA | 1 |
| Kamal, S | 1 |
| Sindi, I | 1 |
| Masaood, R | 1 |
| Choi, JH | 1 |
| Cho, JR | 1 |
| Park, SM | 1 |
| Shaha, KB | 1 |
| Pierres, F | 1 |
| Sumiya, T | 1 |
| Chun, KJ | 1 |
| Kang, MK | 1 |
| Choi, S | 1 |
| Lee, N | 1 |
| Noh, Y | 1 |
| Lee, J | 1 |
| Shin, S | 1 |
| Lim, HS | 1 |
| Bae, SK | 1 |
| Oh, E | 1 |
| Kim, GJ | 1 |
| Kim, JH | 1 |
| Lee, S | 1 |
| Ohata, C | 1 |
| Imamura, T | 1 |
| Shimizu, Y | 1 |
| Minatoguchi, S | 1 |
| Hashimoto, K | 1 |
| Uno, Y | 1 |
| Arai, M | 1 |
| Wang, N | 1 |
| Chen, X | 1 |
| Lu, C | 1 |
| Takemura, G | 1 |
| Shimomura, M | 1 |
| Fujiwara, T | 1 |
| Fujiwara, H | 1 |
| Rajesh, KG | 1 |
| Suzuki, R | 1 |
| Maeda, H | 1 |
| Murio, Y | 1 |
| Sasaguri, S | 1 |
| Sanganalmath, SK | 1 |
| Barta, J | 1 |
| Takeda, N | 2 |
| Kumamoto, H | 2 |
| Dhalla, NS | 2 |
| Tanaka, T | 1 |
| Fujita, M | 1 |
| Nakae, I | 1 |
| Tamaki, S | 1 |
| Hasegawa, K | 1 |
| Kihara, Y | 1 |
| Nohara, R | 1 |
| Sasayama, S | 1 |
| Brasil, D | 1 |
| Temsah, RM | 1 |
| Kumar, K | 1 |
1 trial available for sarpogrelate and Myocardial Infarction
| Article | Year |
|---|---|
Improvement of exercise capacity by sarpogrelate as a result of augmented collateral circulation in patients with effort angina.
Topics: Aged; Aged, 80 and over; Angina Pectoris; Collateral Circulation; Coronary Circulation; Coronary Ves | 1998 |
8 other studies available for sarpogrelate and Myocardial Infarction
| Article | Year |
|---|---|
Therapeutic activity of sarpogrelate and dopamine D
Topics: Animals; Blood Glucose; Bromocriptine; Cabergoline; Diabetes Mellitus, Experimental; Diabetic Nephro | 2021 |
Sarpogrelate Based Triple Antiplatelet Therapy Improved Left Ventricular Systolic Function in Acute Myocardial Infarction: Retrospective Study.
Topics: Biomarkers; Endpoint Determination; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platel | 2017 |
Antiplatelet Therapy of Cilostazol or Sarpogrelate with Aspirin and Clopidogrel after Percutaneous Coronary Intervention: A Retrospective Cohort Study Using the Korean National Health Insurance Claim Database.
Topics: Aspirin; Cilostazol; Clopidogrel; Drug-Related Side Effects and Adverse Reactions; Hemorrhage; Human | 2016 |
Painful purple toes.
Topics: Atherosclerosis; Blue Toe Syndrome; Diagnosis, Differential; Humans; Male; Middle Aged; Myocardial I | 2016 |
The role of serotonin in ischemic cellular damage and the infarct size-reducing effect of sarpogrelate, a 5-hydroxytryptamine-2 receptor blocker, in rabbit hearts.
Topics: Adenosine Triphosphate; Alkaloids; Animals; Benzophenanthridines; Decanoic Acids; Disease Models, An | 2002 |
5-HT2 receptor blocker sarpogrelate prevents downregulation of antiapoptotic protein Bcl-2 and protects the heart against ischemia-reperfusion injury.
Topics: Animals; Apoptosis; Cardiotonic Agents; Caspase 3; Caspases; Down-Regulation; Edema, Cardiac; Heart; | 2006 |
Antiplatelet therapy mitigates cardiac remodeling and dysfunction in congestive heart failure due to myocardial infarction.
Topics: Animals; Arrhythmias, Cardiac; Cilostazol; Disease Models, Animal; Echocardiography; Electrocardiogr | 2008 |
Blockade of 5-HT(2A) receptors by sarpogrelate protects the heart against myocardial infarction in rats.
Topics: Animals; Disease Models, Animal; Electrocardiography; Heart; Heart Conduction System; Male; Myocardi | 2002 |